炎症性肠病成本效益系统综述

数据集获取（Figshare）

• 源站标题：A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease
• DOI：10.1371/journal.pone.0185500
• 发布日期：2017-10-03
• 文件数：4 个
• 文件总体积：828.82 KB
• 源站页面：https://plos.figshare.com/articles/dataset/A_systematic_review_of_cost-effectiveness_studies_comparing_conventional_biological_and_surgical_interventions_for_inflammatory_bowel_disease/5464990

命令行下载

curl -L -o "pone.0185500.s001.pdf" "https://ndownloader.figshare.com/files/9451594"
curl -L -o "pone.0185500.s002.pdf" "https://ndownloader.figshare.com/files/9451630"
curl -L -o "pone.0185500.s003.pdf" "https://ndownloader.figshare.com/files/9451666"
curl -L -o "pone.0185500.s004.pdf" "https://ndownloader.figshare.com/files/9451690"

文件清单

• pone.0185500.s001.pdf（39.26 KB）
• pone.0185500.s002.pdf（188.96 KB）
• pone.0185500.s003.pdf（511.37 KB）
• pone.0185500.s004.pdf（89.23 KB）

文件总体积 828.82 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
Inflammatory bowel disease (IBD) is a chronic disease placing a large health and economic burden on health systems worldwide. The treatment landscape is complex with multiple strategies to induce and maintain remission while avoiding long-term complications. The extent to which rising treatment costs, due to expensive biologic agents, are offset by improved outcomes and fewer hospitalisations and surgeries needs to be evaluated. This systematic review aimed to assess the cost-effectiveness of treatment strategies for IBD.
Materials and methods
A systematic literature search was performed in March 2017 to identify economic evaluations of pharmacological and surgical interventions, for adults diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC). Costs and incremental cost-effectiveness ratios (ICERs) were adjusted to reflect 2015 purchasing power parity (PPP). Risk of bias assessments and a narrative synthesis of individual study findings are presented.
Results
Forty-nine articles were included; 24 on CD and 25 on UC. Infliximab and adalimumab induction and maintenance treatments were cost-effective compared to standard care in patients with moderate or severe CD; however, in patients with conventional-drug refractory CD, fistulising CD and for maintenance of surgically-induced remission ICERs were above acceptable cost-effectiveness thresholds. In mild UC, induction of remission using high dose mesalazine was dominant compared to standard dose. In UC refractory to conventional treatments, infliximab and adalimumab induction and maintenance treatment were not cost-effective compared to standard care; however, ICERs for treatment with vedolizumab and surgery were favourable.
Conclusions
We found that, in general, while biologic agents helped improve outcomes, they incurred high costs and therefore were not cost-effective, particularly for use as maintenance therapy. The cost-effectiveness of biologic agents may improve as market prices fall and with the introduction of biosimilars. Future research should identify optimal treatment strategies reflecting routine clinical practice, incorporate indirect costs and evaluate lifetime costs and benefit

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0185500（source: https://plos.figshare.com/articles/dataset/A_systematic_review_of_cost-effectiveness_studies_comparing_conventional_biological_and_surgical_interventions_for_inflammatory_bowel_disease/5464990）。